Skip to content

The MIND-GUT Digital Pilot Intervention Study

Exploring the Interplay Between Diet, Obesity, Mental Health, and the Gut Microbiome. The MIND-GUT Digital Pilot Intervention Study.

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06374407
Acronym
MINDGUT
Enrollment
126
Registered
2024-04-18
Start date
2024-06-30
Completion date
2026-12-31
Last updated
2024-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, Depressive Symptoms, Dysbiosis, Eating Habit, Obesity, Stress

Keywords

mental health, obesity, mind gut diet, gut microbiome

Brief summary

This 12-week pilot study aims to evaluate the feasibility and effectiveness of a dietary intervention targeting diet, obesity, mental health, and the gut microbiome in promoting weight loss and enhancing mental health among obese men and women aged 30-50. Participants, excluding those with specific medical conditions, will be randomly assigned to either an intervention or control group using a meal planning smartphone app. Clinical assessments will include anthropometry, mental health questionnaires, dietary recalls, and stool sample collections. The study's endpoints include program retention, adherence, changes in body weight, mental health, and gut microbiome diversity. Statistical analyses will evaluate intervention effects and the potential mediating roles of the gut microbiome. This pilot study has implications for health policies, public healthcare, digital health companies, and the biotech and pharmacology industries. Future plans involve a large-scale intervention study in multiple countries with ongoing collaborations.

Detailed description

Objective of the Pilot Study and Study Design: This 12-week randomized pilot intervention study aims to assess the feasibility and effectiveness of a dietary intervention targeting diet, obesity, mental health, and the gut microbiome in promoting weight loss and enhancing mental health among obese individuals aged 30-50. Participant Recruitment and Randomization: Participants aged 30-50, excluding those with specific medical conditions such as psychiatric medication use, food allergies affecting diets, eating disorders, diabetes, polycystic ovary syndrome, sensory deficits, recent antibiotic use, participation in other studies, language limitations, coeliac/inflammatory bowel disease, planned weight management within 3 months, and pregnant/lactating/post-menopausal women, will be recruited for the study. Randomization will be conducted to assign eligible participants to either an intervention or control group using a meal planning smartphone app. Clinical Assessments: Clinical assessments will include anthropometry, mental health questionnaires, dietary recalls, and stool sample collections. Study Endpoints: The study's endpoints include program retention, adherence, changes in body weight, mental health, and gut microbiome diversity. Statistical Analyses: Statistical analyses will evaluate the study feasibility, intervention effects on body weight and mental health changes, and the potential mediating roles of these effects by the gut microbiome. Implications and Future Plans: This pilot study has implications for health policies, public healthcare, digital health companies, and the biotech and pharmacology industries. Future plans involve a large-scale intervention study in multiple countries with ongoing collaborations.

Interventions

BEHAVIORALDietary intervention based on the MIND diet

A 12-week pilot randomized controlled trial (RCT) involving N=126 obese participants (1:1 gender ratio) to assess protocol feasibility, including recruitment, retention, compliance, physical examinations, and gut sample collection. Sample size, calculated by a statistician, expects a 5% body weight change at follow-up (std. dev. 10%). We chose a 12-week duration for this pilot study to allow sufficient time to observe significant changes in both body weight and mental health.

Sponsors

State University of New York - Downstate Medical Center
CollaboratorOTHER
Albert Einstein College of Medicine
CollaboratorOTHER
Göteborg University
CollaboratorOTHER
Uppsala University
CollaboratorOTHER
Kristianstad University
CollaboratorOTHER
University of Pavia
CollaboratorOTHER
The Food Scientist AB (Sweden)
CollaboratorUNKNOWN
University of Skövde
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Participants will be blinded to their group assignment and will use a smartphone app for meal planning. However, those in the intervention group may have some awareness of their assignment due to specific food choices. Meanwhile, the control group will have access to a variety of foods and recipes, maintaining blinding between the groups regarding their assigned diets, addressing a common challenge in diet intervention studies.

Intervention model description

We plan to randomly assign participants to either the intervention or control group.

Eligibility

Sex/Gender
ALL
Age
30 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* age 30- 50; * BMI ≥ 30 kg/m2; * stable physical activity; * one person per household; * commitment to full protocol.

Exclusion criteria

* use of psychiatric medications (e.g., serotonin reuptake inhibitors); * use of weight loss medications (GLP-1 receptor agonists); * food allergies affecting adherence to the MIND diet; * diagnosis of eating disorders; * diagnosis of diabetes; * diagnosis of polycystic ovary syndrome; * sensory deficits (e.g., COVID-19-induced loss of taste/smell); * antibiotic use during the latest 3 months; * participation in another study; * language understanding limitations (i.e., not able to understand either Swedish or English); - coeliac/inflammatory bowel disease; * planned weight management program within three months; * pregnancy; * lactation; * menopause.

Design outcomes

Primary

MeasureTime frameDescription
Program retention12 weeksEvaluation of participants' continued engagement in the program over time i.e., % of individuals completing the second and third 24h diet recall and % of participants returning to the second visit at the end of the intervention.
Adherence12 weeksMeasurement of participants' compliance with the assigned diet and program through 24h recall interviews, assessed comparing reported intake frequencies of each food group with the recommended intake frequencies according to the principles of the MIND diet.
Acceptability12 weeksAssessment of participants' experience of the program through qualitative interviews, focusing in particular on: Perception of and experience with the intervention, intervention components (dietary plans, use of the app, etc.), factors influencing participants' engagement, perceived impact on behavior and well-being, interaction with the staff, suggestions for improvement.
Study effectiveness: change in eating attitudes at follow-up12 weeksComparison of a score calculated after administration of the EAT-26 questionnaire at baseline vs. follow-up. The EAT-26 comprises three subscales, namely, Dieting, Bulimia and Food Preoccupation, and Oral Control. Higher scores correspond to a worse outcome.
Study effectiveness: change in stress levels at follow-up12 weeksComparison of PSS-4 questionnaire at baseline vs. follow-up. The PSS total score is calculated by reverse-coding the positive items and summing the scores for all items. The total scores range from 0 to 56, from 0 to 40, and from 0 to 16 for the PSS-14, PSS-10, and PSS-4, respectively. A higher score indicates more perceived stress.
Study effectiveness: change in depression symptoms at follow-up12 weeksComparison of PHQ-9 questionnaire at baseline vs. follow-up. The PHQ-9 is a tool to assist clinicians in identifying and diagnosing major depression. It has a maximum score of 27. Higher scores correspond to worst outcomes in terms of depression symtoms.
Study effectiveness: change in anxiety symtoms at follow-up12 weeksComparison of GAD-7 questionnaire at baseline vs. follow-up. Each item is scored on a four-point Likert scale (0-3) with total scores ranging from 0 to 21 with higher scores reflecting worst outcomes in terms of anxiety severity.
Study effectiveness: change in body weight at follow-up12 weeksComparison of body weight at baseline vs. follow-up
Study effectiveness: change in % total fat mass at follow-up12 weeksComparison of body % total fat mass at baseline vs. follow-up
Study effectiveness: change in % visceral fat mass at follow-up12 weeksComparison of body % visceral fat at baseline vs. follow-up
Study effectiveness: change in waist circumference at follow-up12 weeksComparison of waist circumference at baseline vs. follow-up
Study effectiveness: change in hip circumference at follow-up12 weeksComparison of hip circumference at baseline vs. follow-up
Study effectiveness: change in microbiome variety at follow-up12 weeksComparison of number and types of species at baseline vs. follow-up.

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026